Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arbutus Biopharma stock

Learn how to easily invest in Arbutus Biopharma stock.

Arbutus Biopharma Corp is a biotechnology business based in the US. Arbutus Biopharma shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma employs 85 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arbutus Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Arbutus Biopharma stock price (NASDAQ: ABUS)

Use our graph to track the performance of ABUS stocks over time.

Arbutus Biopharma shares at a glance

Information last updated 2022-07-01.
Latest market close$2.80
52-week range$1.93 - $6.50
50-day moving average $2.49
200-day moving average $3.25
Wall St. target price$6.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.71

Buy Arbutus Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arbutus Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arbutus Biopharma price performance over time

Historical closes compared with the close of $2.8 from 2022-07-01

1 week (2022-06-28) 7.28%
1 month (2022-06-01) N/A
3 months (2022-04-05) -8.79%
6 months (2022-01-03) -29.65%
1 year (2021-07-02) -5.08%
2 years (2020-07-02) 48.94%
3 years (2019-07-05) 24.44%
5 years (2017-07-05) 3.75

Arbutus Biopharma financials

Revenue TTM $21.5 million
Gross profit TTM $-54,514,000
Return on assets TTM -21.82%
Return on equity TTM -54.02%
Profit margin 0%
Book value $1.12
Market capitalisation $403.1 million

TTM: trailing 12 months

Arbutus Biopharma share dividends

We're not expecting Arbutus Biopharma to pay a dividend over the next 12 months.

Have Arbutus Biopharma's shares ever split?

Arbutus Biopharma's shares were split on a 1:5 basis on 3 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma shares which in turn could have impacted Arbutus Biopharma's share price.

Arbutus Biopharma share price volatility

Over the last 12 months, Arbutus Biopharma's shares have ranged in value from as little as $1.93 up to $6.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma's is 2.6588. This would suggest that Arbutus Biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arbutus Biopharma overview

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc. ; Gritstone Oncology, Inc. ; Alnylam Pharmaceuticals, Inc. ; Qilu Pharmaceuticals Co, Ltd.

Frequently asked questions

What percentage of Arbutus Biopharma is owned by insiders or institutions?
Currently 27.109% of Arbutus Biopharma shares are held by insiders and 29.821% by institutions.
How many people work for Arbutus Biopharma?
Latest data suggests 85 work at Arbutus Biopharma.
When does the fiscal year end for Arbutus Biopharma?
Arbutus Biopharma's fiscal year ends in December.
Where is Arbutus Biopharma based?
Arbutus Biopharma's address is: 701 Veterans Circle, Warminster, PA, United States, 18974
What is Arbutus Biopharma's ISIN number?
Arbutus Biopharma's international securities identification number is: CA03879J1003
What is Arbutus Biopharma's CUSIP number?
Arbutus Biopharma's Committee on Uniform Securities Identification Procedures number is: 03879J100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site